Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
Marks first international filing for Evofem’s single-dose oral treatment
India currently hosts more than 10,075 biotech startups
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
The collaboration is expected to facilitate access to world-class treatments and specialised care for Iraqi personnel
First fully automated, cartridge-based companion diagnostic test for colorectal cancer patients approved in the United States
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval
RTX001 represents a groundbreaking advance in the treatment of end-stage liver disease, offering new hope for patients with limited options
Brenntag Specialties will provide pharmaceutical manufacturers and biopharmaceutical companies with a reliable supply of high-purity, GMP-compliant acetates
Subscribe To Our Newsletter & Stay Updated
